Schering-Plough effects mask Merck & Co's underlying profit growth
This article was originally published in Scrip
Merck & Co saw its net profit attributable to the company tumble from $1.43 billion to $299 million in the first full quarter following the closure of its merger with Schering-Plough. However, when purchase accounting, restructuring and merger-related costs are stripped out, net profit stood at $2.61 billion. EPS fell from $0.67 to $0.09, although when adjusted the figure was $0.83, up from $0.74 a year before.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.